Advertisement

Medical Oncology

, 35:65 | Cite as

Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment

  • Jae-Joon Kim
  • Jihoon Kang
  • Yong Sang Hong
  • Kyu-pyo Kim
  • Sun Young Kim
  • Tae Won Kim
  • Jeong Eun Kim
Original Paper
  • 201 Downloads

Abstract

Because the number of cytotoxic agents available for the treatment of metastatic colorectal cancer (mCRC) is limited, rechallenge with the same chemotherapy agents can provide a continuum of treatment. This study investigated the efficacy and feasibility of oxaliplatin rechallenge in mCRC patients who had been previously exposed to oxaliplatin-based chemotherapy. Patients were included if they had mCRC and evaluable disease, had remained disease-free or progression-free for at least 6 months after the last dose of prior oxaliplatin-based therapy, and were retreated with oxaliplatin therapy. Between January 2009 and May 2014, 110 patients were retreated with oxaliplatin-based regimens; of these, 42 (38.2%) had received prior oxaliplatin as adjuvant chemotherapy and 68 (61.8%) as palliative chemotherapy. The overall response rate to oxaliplatin rechallenge was 30.9% (34/110), and the disease control rate was 68.2% (75/110), with one patient achieving complete response, 33 achieving partial response, and 41 having stable disease. Median progression-free survival and overall survival following oxaliplatin rechallenge were 5.9 months (95% confidence interval [CI], 4.4–7.4 months) and 18.5 months (95% CI, 14.0–23.0 months), respectively. Sixteen patients experienced grade 2 or 3 neuropathy. Ten patients experienced any grade hypersensitivity reaction within four cycles of treatment, including six who stopped treatment due to grade 3 or 4 hypersensitivity reactions. Rechallenge with oxaliplatin-based therapy may be an option for patients who achieve at least 6 months of disease-free or progression-free survival with prior oxaliplatin-based chemotherapy. However, neurotoxicity and hypersensitivity reactions should be carefully monitored in this setting.

Keywords

Metastatic colon cancer Oxaliplatin Rechallenge Chemotherapy 

Notes

Funding

This study was supported by Grant 2015-1083 from the Asan Institute for Life Sciences, Seoul, Korea.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no competing interests.

Informed consent

Informed consent was obtained from all individual participants include in the study.

References

  1. 1.
    Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol. 1998;25(2 Suppl 5):23–31.PubMedGoogle Scholar
  2. 2.
    Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol. 1998;9:105–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25:1346–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O’Neil BH, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(18 suppl):LBA3.CrossRefGoogle Scholar
  7. 7.
    Chibaudel B, Tournigand C, Bonnetain F, Maindrault-Goebel F, Lledo G, Andre T, et al. Platinum-sensitivity in metastatic colorectal cancer: towards a definition. Eur J Cancer. 2013;49:3813–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Dev Ther. 2015;9:3099–108.CrossRefGoogle Scholar
  9. 9.
    Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306:752–5.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.CrossRefPubMedGoogle Scholar
  13. 13.
    Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.CrossRefPubMedGoogle Scholar
  14. 14.
    Costa T, Nunez J, Felismino T, Boente L, Mello C. REOX: evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study. Clin Colorectal Cancer. 2017;16:316–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Kanat O, Ertas H, Caner B. Platinum-induced neurotoxicity: a review of possible mechanisms. World J Clin Oncol. 2017;8:329–35.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27:5727–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol. 2006;24:394–400.CrossRefPubMedGoogle Scholar
  18. 18.
    Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology. 2009;76:36–41.CrossRefPubMedGoogle Scholar
  19. 19.
    Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89:477–81.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mori Y, Nishimura T, Kitano T, Yoshimura K, Matsumoto S, Kanai M, et al. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology. 2010;79:136–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Shibata Y, Ariyama H, Baba E, Takii Y, Esaki T, Mitsugi K, et al. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol. 2009;14:397–401.CrossRefPubMedGoogle Scholar
  22. 22.
    Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol. 2001;12:132–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Newman Taylor AJ, Cullinan P, Lympany PA, Harris JM, Dowdeswell RJ, du Bois RM. Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Respir Crit Care Med. 1999;160:435–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Toki MI, Saif MW, Syrigos KN. Hypersensitivity reactions associated with oxaliplatin and their clinical management. Expert Opin Drug Saf. 2014;13:1545–54.CrossRefPubMedGoogle Scholar
  25. 25.
    Aroldi F, Prochilo T, Bertocchi P, Zaniboni A. Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J Chemother. 2015;27:63–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jae-Joon Kim
    • 1
  • Jihoon Kang
    • 1
  • Yong Sang Hong
    • 1
  • Kyu-pyo Kim
    • 1
  • Sun Young Kim
    • 1
  • Tae Won Kim
    • 1
  • Jeong Eun Kim
    • 1
  1. 1.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea

Personalised recommendations